Director, Biostatistics
Summit Therapeutics · Remote · US only
$246k–$290k/yr
Summit TherapeuticsRemote · US only
$190k–$237k/yr listed by the employer
On Summit Therapeutics’ own careers site (Greenhouse), checked open today.
Summarised from the posting by AI and can be wrong. The full description is the source.
Sign in and add your resume to see which of this job's requirements it shows.
Sign in to check your matchSaved to your account, encrypted. The AI that reads it doesn't keep it or train on it.
From Summit Therapeutics’ careers site
About Summit:
Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.
Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:
Non-small Cell Lung Cancer (NSCLC)
-
HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.
-
HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.
-
HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.
Colorectal Cancer (CRC)
-
HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.
Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.
Overview:
Summit Therapeutics is seeking a Director, Value Outcomes Liaison (VOL), to join our mission of developing Ivonescimab, a novel and unique immunotherapy with the potential to help patients suffering from life-threatening cancers.
The Director, VOL is a critical member of an expanding team, responsible for interfacing with US population-based decision makers (PBDMs) including payers, health systems, clinical pathway organizations, P&T committees, and policy makers. The VOL educates key stakeholders on clinical, economic, and humanistic impact of ivonescimab to help inform formulary access, pathway/guideline decisions, and improve lives of cancer patients. Providing objective and scientifically sound medical information on ivonescimab and the relevant disease states through use of economic models, outcomes tools, educational programs, and collaborations to enhance key stakeholder recognition of Summit Therapeutics. The VOL will compliantly partner with the commercial market access field team to facilitate access to ivonescimab through proactive engagement with organized customers, ensuring the delivery of accurate, non-promotional medical information.
Roles and responsibilities:
Experience/Education:
This is the pay for this position
Pay Transparency
$190,000—$237,000 USD
Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation.
Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit’s Talent Acquisition team at recruiting@smmttx.com to obtain prior written authorization before referring any candidates to Summit.
Summit Therapeutics Inc. is an Equal Opportunity Employer and takes pride in creating and maintaining diverse environment. We do not discriminate in recruitment, hiring, training or promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status.
Something wrong with this job? Report it · This flag looks wrong
Summit Therapeutics · Remote · US only
$246k–$290k/yr
Looks goodOpen 8 monthsChecked open todayPosted 8 months ago
Summit Therapeutics · Remote · US only
$190k–$237k/yr
StrongChecked open todayPosted 17 days ago
Summit Therapeutics · Remote · US only
$192k–$239k/yr
StrongChecked open todayPosted 1 month ago
Summit Therapeutics · Remote · US only +1 place
$237k–$296k/yr
StrongChecked open todayPosted 1 month ago
Summit Therapeutics · Remote · location not stated
$190k–$237k/yr
StrongChecked open todayPosted 1 month ago
Summit Therapeutics · Remote · location not stated
$169k–$198k/yr
StrongChecked open todayPosted 1 month ago